Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of etretinate and triamcinolone acetonide. **Etretinate** is a second-generation synthetic aromatic retinoid used primarily for the treatment of severe psoriasis and other keratinization disorders. Its mechanism involves binding to retinoic acid receptors (RARs), acting as an agonist to modulate gene expression involved in cell differentiation and proliferation, particularly affecting keratinocytes[2][3][6]. Etretinate was withdrawn from several markets due to its long half-life and risk of teratogenicity but remains notable for its efficacy in dermatological conditions[2][6]. **Triamcinolone acetonide** is a synthetic corticosteroid with anti-inflammatory, immunosuppressive, and antipruritic properties. It acts by binding to glucocorticoid receptors, inhibiting inflammatory mediators and suppressing immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etretinate + triamcinolone acetonide.